Literature DB >> 18816787

What is the role of serological markers in the diagnosis of IBD?

Marla C Dubinsky1.   

Abstract

Research and technological advancements have fostered a novel approach to understanding the intricate relationship between genetic and clinical expression of disease. Both genetic and serum antibody markers hold the most promise in helping researchers better comprehend disease heterogeneity and natural history. Although our current gold standard diagnostic tests do not possess this capability, exciting preliminary research suggests IBD-specific antibody markers may serve as predictors of an individual's disease course. Thus, the foundation has been laid upon which the discovery of novel IBD-specific and IBD-sensitive markers will enable researchers to identify at-risk individuals, as well as diagnose IBD and stratify patients into homogeneous subtypes with certainty. Clinicians can then create and implement individual treatment plans designed to improve the long-term prognosis of these chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18816787     DOI: 10.1002/ibd.20585

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  7 in total

Review 1.  Clinical Utility of Biomarkers in IBD.

Authors:  Gerhard Rogler; Luc Biedermann
Journal:  Curr Gastroenterol Rep       Date:  2015-07

2.  Maternal Outcomes and Pregnancy-Related Complications Among Hospitalized Women with Inflammatory Bowel Disease: Report from the National Inpatient Sample.

Authors:  Daniela Guerrero Vinsard; Raffi Karagozian; Dorothy B Wakefield; Sunanda V Kane
Journal:  Dig Dis Sci       Date:  2021-08-18       Impact factor: 3.487

3.  Personalized Medicine: Yesterday, Today, and Tomorrow.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-12

4.  Serological markers for inflammatory bowel disease in AIDS patients with evidence of microbial translocation.

Authors:  Anupa Kamat; Petronela Ancuta; Richard S Blumberg; Dana Gabuzda
Journal:  PLoS One       Date:  2010-11-15       Impact factor: 3.240

Review 5.  How to predict clinical relapse in inflammatory bowel disease patients.

Authors:  Elisa Liverani; Eleonora Scaioli; Richard John Digby; Matteo Bellanova; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

6.  Serologic Reactivity Reflects Clinical Expression of Ulcerative Colitis in Children.

Authors:  Elizabeth A Spencer; Sonia M Davis; David R Mack; Brendan M Boyle; Anne M Griffiths; Neal S LeLeiko; Cary G Sauer; David J Keljo; James F Markowitz; Susan S Baker; Joel R Rosh; Robert N Baldassano; Maria Oliva-Hemker; Marian D Pfefferkorn; Anthony R Otley; Melvin B Heyman; Joshua D Noe; Ashish S Patel; Paul A Rufo; M Alison Marquis; Thomas D Walters; Margaret H Collins; Subra Kugathasan; Lee A Denson; Jeffrey S Hyams; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2018-05-18       Impact factor: 5.325

Review 7.  Fungal microbiome in inflammatory bowel disease: a critical assessment.

Authors:  David M Underhill; Jonathan Braun
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.